泛I类PI3K抑制剂布帕利塞联合西妥昔单抗治疗复发或转移性头颈癌的初步研究
该初步研究评估了PI3K抑制剂布帕利塞与西妥昔单抗联用治疗复发或转移性头颈鳞状细胞癌的最大耐受剂量。方案最大耐受剂量为布帕利塞每日100 mg联合西妥昔单抗每14天静脉给药,未观察到剂量限制性毒性,1例部分缓解、4例疾病稳定。
要点
- 布帕利塞每日100 mg联合西妥昔单抗方案耐受性良好。
- 剂量递增阶段未观察到剂量限制性毒性。
- 既往接受西妥昔单抗单药治疗的患者可从联合方案中获益。
核心结论
- 布帕利塞每日100 mg联合西妥昔单抗在该初步研究中耐受性良好。
- 既往接受西妥昔单抗单药治疗的患者显示从联合方案中获益。
研究设计与样本
- 布帕利塞口服从第7天开始每日给药,采用3+3设计递增剂量,随后扩展队列6例。
- 西妥昔单抗从第0天开始每14天静脉给药。
主要发现
- 10例患者既往接受过≥2线治疗,11例既往接受过西妥昔单抗。
- 剂量递增期间未观察到剂量限制性毒性。
- 1例患者达到部分缓解,4例达到疾病稳定。
关键数值与推荐
- 方案最大耐受剂量为布帕利塞每日100 mg联合西妥昔单抗每14天静脉给药。
临床怎么用
- 该联合方案可作为复发或转移性头颈鳞状细胞癌的潜在治疗选择,尤其对既往西妥昔单抗治疗者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). METHODS: Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparlisib starting day 7 and daily thereafter. The dose of buparlisib was escalated in a 3 + 3 design followed by a dose expansion cohort of 6 patients. The MTD of buparlisib per protocol was 100 mg daily with cetuximab given intravenously every 14 days starting day 0. RESULTS: Ten patients had ≥2 previous treatment regimens (11 with prior cetuximab). There were no dose limiting toxicities observed during dose escalation. One patient achieved a partial response and 4 achieved stable disease. CONCLUSION: Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination.
引用
- Brisson RJ, Kochanny S, Arshad S, et al. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019. PMID: 31486207. doi:10.1002/hed.25910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。